Ze Su
机构：Guangxi Medical University, Guangxi Center for Disease Prevention and Control, First People's Hospital of Nanning
发表论文 34 篇 · 总被引 73 次 · h-index 4
代表论文
- Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 27)
- Systematic treatment in unresectable hepatocellular carcinoma: The most concerns (2024 · iLiver · 被引 9)
- Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004) (2025 · JHEP Reports · 被引 7)
- Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multi-center study (2025 · Liver Cancer · 被引 6)
- Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study (2026 · Liver Cancer · 被引 4)
- Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 4)